The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study

Nowiński, Adam; Puścińska, Elżbieta; Goljan, A; Peradzyńska, Joanna; Bednarek, Michał; Korzybski, Damian; Kamiński, D; Stokłosa, Anna; Czystowska, Monika; Śliwiński, Paweł; Górecka, Dorota

doi:10.1111/crj.12398

Cited by 36 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This rate remained stable throughout the study period, but tended to decline with increasing age, whereas sarcoidosis notification as a NUCD increased with age. We speculate that this could be caused by 1) a decreased severity of sarcoidosis in the elderly [23] or 2) the accumulation of comorbidities and/or complications in the elderly [16]. Such variations have been frequently reported in other MCOD analyses [24].…”

Section: Discussionmentioning

confidence: 72%

Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis

et al. 2016

View full text Add to dashboard Cite

Objectives We investigate the reporting of obesity on death certificates in three countries (France, Italy, and the United States) with different levels of prevalence, and we examine which causes are frequently associated with obesity. Methods We use cause-of-death data for all deaths at ages 50-89 in 2010-2011. Since obesity may not be the underlying cause (UC) of death, we compute age-and sex-standardized death rates considering all mentions of obesity (multiple causes or MC). We use cluster analyses to identify patterns of cause-of-death combinations. Results Obesity is selected as UC in no more than 20% of the deaths with a mention of obesity. Mortality levels, whether measured from the UC or the MC, are weakly related to levels of prevalence. Patterns of cause-of-death combinations are similar across the countries. In addition to strong links with cardiovascular diseases and diabetes, we identify several less familiar associations. Conclusions Considering all mentions on the deaths certificates reduces the underestimation of obesity-related mortality based on the UC only. It also enables us to describe the various mortality patterns involving obesity.

show abstract

Section: Discussionmentioning

confidence: 72%

Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Available evidence suggests that comorbidities substantially affect disease progression and survival in IPF [7,8], but information on other ILD subtypes is sparse [9,10]. Moreover, previous research has often focused on distinct conditions [11][12][13][14] instead of the patients' entire comorbidity burden [15][16][17] and, consequently, has tended to disregard the effects of pharmaceutical comorbidity management [8,10,[18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis

Schwarzkopf¹,

Witt²,

Waelscher

et al. 2018

Idiopathic Interstitial Pneumonias

View full text Add to dashboard Cite

Background: Interstitial lung diseases (ILDs) are associated with a high burden of disease. However, data on the prognostic impact of comorbidities and comorbidity-related pharmaceutical treatments in patients with various ILDs remain sparse. Methods: Using longitudinal claims data from a German Statutory Health Insurance Fund, we assessed comorbidity in ILD subtypes and associated drug treatments. Baseline comorbidity was assessed via the Elixhauser Comorbidity Index that was amended by ILD-relevant conditions. Drug treatment was assessed on the substance level using the ATC-codes of drugs prescribed at the time of ILD diagnosis. Subsequently, the comorbid conditions (main analysis) and pharmaceutical substances (secondary analysis) with a meaningful association to survival were identified for the complete ILD cohort and within the subtype strata. For this, we applied multivariate Cox models using a LASSO selection process and visualized the findings within comorbidomes. Results: In the 36,821 patients with ILDs, chronic obstructive pulmonary disease (COPD), arterial hypertension, and ischaemic heart disease (IHD) were the most prevalent comorbidities. The majority of patients with cardiovascular diseases received pharmaceutical treatment, while, in other relevant comorbidities, treatment quotas were low (COPD 46%, gastro-oesophageal reflux disease 65%). Comorbidities had a clinically meaningful detrimental effect on survival that tended to be more pronounced in the case of untreated conditions (e.g. hazard ratios for treated IHD 0.97 vs. 1.33 for untreated IHD). Moreover, comorbidity impact varied substantially between distinct subtypes. Conclusions: Our analyses suggest that comorbid conditions and their treatment profile significantly affect mortality in various ILDs. Therefore, comprehensive comorbidity assessment and management remains important in any ILD.

show abstract

“…Comorbidities may also importantly impact QoL and are more prevalent in patients with sarcoidosis compared to the normal population [41,86,87]. A higher number of comorbidities is associated with more frequent hospitalizations and a higher mortality rate [87,88]. The development of new comorbidities, related either to steroid use or to sarcoidosis itself, after the diagnosis of sarcoidosis is independently and strongly associated with a number of adverse outcomes, including worse QoL, risk of hospitalization, and financial impacts [4].…”

Section: Antidepressants Anticonvulsants Topical Anestheticsmentioning

confidence: 99%

Comprehensive Care for Patients with Sarcoidosis

Moor

Kahlmann

Culver

et al. 2020

JCM

View full text Add to dashboard Cite

Sarcoidosis is a multisystem granulomatous disease, associated with significant morbidity and impaired quality of life. Treatment is aimed at recovering organ function, reducing symptom burden and improving quality of life. Because of the heterogeneity and variable disease course, a comprehensive, multidisciplinary approach to care is needed. Comprehensive care includes not only pharmacological interventions, but also supportive measures aimed at relieving symptoms and improving quality of life. The purpose of this review is to summarize the most recent knowledge regarding different aspects of care and propose a structured approach to sarcoidosis management.

show abstract

The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study

Abstract: The comorbidity burden has strong impact on mortality in sarcoidosis. Thyroid diseases are more frequent in sarcoidosis than in non-sarcoid controls.

Cited by 36 publications

References 30 publications

Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis

Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis

Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis

Comprehensive Care for Patients with Sarcoidosis

Contact Info

Product

Resources

About